Literature DB >> 18765551

Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas.

Zhong Jiang1, Peigou G Chu, Bruce A Woda, Qin Liu, K C Balaji, Kenneth L Rock, Chin-Lee Wu.   

Abstract

PURPOSE: To create an easily applicable system based on a combination of the quantitative level of IMP3 (an oncofetal protein) and tumor stage to more accurately predict postoperative metastasis of localized renal cell carcinoma. EXPERIMENTAL
DESIGN: Three hundred sixty nine patients with localized renal cell carcinoma (without metastasis during nephrectomy) were investigated by the use of survival analysis. The expression of IMP3 was evaluated by immunohistochemistry and quantitated with a computerized image analyzer. Based on combining quantitative IMP3 results with tumor staging (QITS system), patients were divided into four distinct risk groups for the development of metastasis.
RESULTS: The four groups of patients in the QITS system showed significant differences in their metastasis-free (P<0.0001) and overall survivals (P<0.0001). Almost all patients of group IV with localized renal cell carcinomas developed metastasis and died after nephrectomy. The 5- and 10-year metastasis-free survival rates for the QITS groups were as follows: for group I, 97% and 91%; II, 62% and 55%; III, 46% and 19%; and IV, 17% and 4%, respectively. The 5- and 10-year overall survival rates for the QITS groups were as follows: for group I, 89% and 72%; II, 58% and 41%; III, 38% and 17%; and IV, 14% and 4%, respectively.
CONCLUSIONS: The QITS is a simple and accurate system for the prediction of tumor metastasis. This system not only provides important prognostic information but also can be used at initial diagnosis of localized renal cell carcinoma to identify high-risk patients who may benefit from early systematic therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18765551     DOI: 10.1158/1078-0432.CCR-08-0504

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  33 in total

1.  Downregulation of tNASP inhibits proliferation through regulating cell cycle-related proteins and inactive ERK/MAPK signal pathway in renal cell carcinoma cells.

Authors:  Jianzheng Fang; Hainan Wang; Wei Xi; Gong Cheng; Shangqian Wang; Shifeng Su; Shengli Zhang; Yunfei Deng; Zhen Song; Aiming Xu; Bianjiang Liu; Jingyi Cao; Zengjun Wang
Journal:  Tumour Biol       Date:  2015-02-12

2.  IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status.

Authors:  Emanuel Adelino M Damasceno; Fabiana Pirani Carneiro; Albino Verçosa de Magalhães; Marcos de Vasconcelos Carneiro; Gustavo Henrique Soares Takano; Leonora Maciel de Sousa Vianna; Heinrich Bender Kohnert Seidler; Tercia Maria Mendes Lousa de Castro; Maria Imaculada Muniz-Junqueira; Rivadávio Fernandes Batista Amorim; Vânia Maria Moraes Ferreira; Andrea Barreto Motoyama
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-17       Impact factor: 4.553

3.  Effects of the novel heat shock protein 90 inhibitor AUY922 in renal cell carcinoma ACHN and 786-O cells.

Authors:  Jingjuan Zhu; Yanbiao Zhu; Weiwei Qi; Wensheng Qiu
Journal:  Oncol Lett       Date:  2015-06-02       Impact factor: 2.967

4.  Decreased expression of NPRL2 in renal cancer cells is associated with unfavourable pathological, proliferation and apoptotic features.

Authors:  Yongyong Tang; Li Jiang; Wei Tang
Journal:  Pathol Oncol Res       Date:  2014-05-01       Impact factor: 3.201

5.  Cancer-associated fibroblasts promote renal cell carcinoma progression.

Authors:  Yunze Xu; Yongning Lu; Jiajia Song; Baijun Dong; Wen Kong; Wei Xue; Jin Zhang; Yiran Huang
Journal:  Tumour Biol       Date:  2015-01-23

6.  Integrative genome comparison of primary and metastatic melanomas.

Authors:  Omar Kabbarah; Cristina Nogueira; Bin Feng; Rosalynn M Nazarian; Marcus Bosenberg; Min Wu; Kenneth L Scott; Lawrence N Kwong; Yonghong Xiao; Carlos Cordon-Cardo; Scott R Granter; Sridhar Ramaswamy; Todd Golub; Lyn M Duncan; Stephan N Wagner; Cameron Brennan; Lynda Chin
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

7.  Foxl1 inhibits tumor invasion and predicts outcome in human renal cancer.

Authors:  Feng-Qiang Yang; Feng-Ping Yang; Wei Li; Min Liu; Guang-Chun Wang; Jian-Ping Che; Jian-Hua Huang; Jun-Hua Zheng
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

8.  Up-regulation of miR-630 in clear cell renal cell carcinoma is associated with lower overall survival.

Authors:  Jian-Jun Zhao; Peng-Jie Chen; Rui-Qin Duan; Ke-Ji Li; Yu-Zhong Wang; Yong Li
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

9.  Protein phosphatase-2A is down-regulated in patients within clear cell renal cell carcinoma.

Authors:  Jun Li; Chang Sheng; Wei Li; Jun-Hua Zheng
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

10.  Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma.

Authors:  Yi-Jun Xue; Ri-Hai Xiao; Da-Zhi Long; Xiao-Feng Zou; Xiao-Ning Wang; Guo-Xi Zhang; Yuan-Hu Yuan; Geng-Qing Wu; Jun Yang; Yu-Ting Wu; Hui Xu; Fo-Lin Liu; Min Liu
Journal:  J Transl Med       Date:  2012-09-24       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.